Relevant bibliographies by topics / N.T. Luke II / Journal articles
To see the other types of publications on this topic, follow the link: N.T. Luke II.

Journal articles on the topic 'N.T. Luke II'

Author: Grafiati
Published: 4 June 2021
Last updated: 16 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'N.T. Luke II.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Wang, Jie, Adam S. Asch, Nada Hamad, Andrew Weickhardt, Monika Tomaszewska-Kiecana, Monika Dlugosz-Danecka, Halyna Pylypenko, et al. "A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma." Blood 136, Supplement 1 (November 5, 2020): 21–22. http://dx.doi.org/10.1182/blood-2020-139868.

Full text
Abstract:
Background: MGD013 is an investigational, first-in-class, Fc-bearing bispecific tetravalent DART molecule designed to bind PD-1 and LAG-3 and sustain/restore the function of exhausted T cells (1). MGD013 demonstrates in vitro ligand blocking properties and improved T-cell responses beyond that observed with anti-PD-1 and anti-LAG-3 benchmark antibodies alone or in combination. PD-1 targeted therapy with nivolumab in patients (pts) with relapsed or refractory (R/R) diffuse large B cell lymphoma (DLBCL) has yielded modest efficacy (2). LAG-3, highly expressed in DLBCL (3), has emerged as another therapeutic target of interest in this population with continued unmet need. Methods: This study characterizes the safety, tolerability, dose-limiting toxicities, maximum tolerated dose, PK/PD, and antitumor activity of MGD013 in pts with advanced solid and hematologic malignancies. R/R DLBCL pts are being treated at the recommended Phase 2 dose of 600 mg every two weeks in Cohort Expansion. Results: At data-cutoff, 17 DLBCL pts received MGD013 (2.5 median prior lines of therapy, 41.2% with prior CAR-T therapy). Treatment-related adverse events (TRAEs) occurred in 11/17 (64.7%) pts, with no same TRAE occurring in > 1 patient except pyrexia (n=3). One grade ≥ 3 TRAE occurred (pneumonia), and no events of tumor lysis syndrome were observed. Among 11 response-evaluable pts (i.e. received at least one on-treatment scan), 1 complete response (CR) and 3 partial responses (PRs) per the Lugano Classification were observed. Analyses of available pre-treatment tumor biopsy samples corresponding to responding pts demonstrated relatively high levels of LAG-3, PD-1, and PD-L1 by IHC. More comprehensive translational analyses were undertaken for the pt with CR, observed after a single MGD013 infusion in a 28-year-old male in relapse 6 months after CD19-directed CAR T-cell therapy. In contrast to a pre-CAR T biopsy specimen demonstrating no LAG-3 or PD-1 expression, IHC analysis of a lymph node specimen biopsied post-CAR T and prior to MGD013 treatment revealed high levels of both LAG-3 and PD-1 on both infiltrating T-cells and malignant B-cells. Consistent with CD19 CAR T resistance, no CD19 expression was evident. MHC class II and PD-L1 expression were observed, which when bound to LAG-3 and PD-1, respectively, form immune checkpoints that can decrease T cell function. Following MGD013 treatment, serum IFN-γ markedly increased to >140-fold above baseline. No significant changes were observed for IL-6 or IL-2. Expansion of circulating CD3+CD8+ and CD3+CD4-CD8- T-cell subsets and associated cytolytic markers (i.e., perforin, granzyme B) were observed following MGD013 treatment. The patient underwent allogeneic stem cell transplant (allo-SCT) and remains in remission 14 months post-MGD013 and 12 months post-allo-SCT. Further correlative biomarker analyses are underway in the ongoing clinical trial. Conclusion: MGD013, a novel molecule designed to coordinately block PD-1 and LAG-3, has preliminarily demonstrated an acceptable safety profile and encouraging early evidence of anti-tumor activity in R/R DLBCL pts with and without prior treatment with CAR T. Biomarker analyses confirmed expression of both PD-1 and LAG-3 axes in responding pts with evidence of pharmacodynamic responses consistent with the ability of MGD013 to enhance T-cell function. References: 1. Luke JJ, Patel MR, Hamilton E, et al. A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms. J Clin Oncol 38: 2020 (suppl; abstr 3004). 2. Keane C, Law SC, Gould C, et al. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Adv. 2020;4(7):1367-1377. doi:10.1182/bloodadvances.2019001390 3. Ansell SM, Minnema MC, Johnson P, et al., Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. J Clin Oncol, 2019. 37(6): p. 481-489. Disclosures Wang: Verastem Oncology: Membership on an entity's Board of Directors or advisory committees; Curio Science: Honoraria; Putnam LLC: Honoraria. Asch:Astellas Pharma: Research Funding; Cartesian: Research Funding; Forty Seven: Research Funding; Juno: Research Funding; MacroGenics: Research Funding; MEI Pharma: Patents & Royalties: Provisional patent submitted (I), Research Funding. Hamad:Novartis: Honoraria; Abbvie: Honoraria. Weickhardt:Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding; Ipsen: Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Ulahannan:Merck Co. Inc: Research Funding; Bayer: Membership on an entity's Board of Directors or advisory committees; G1 Therapeutics, Inc.: Research Funding; ArQule, Inc.: Research Funding; Evelo Biosciences, Inc.: Research Funding; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding; Klus Pharma, Inc.: Research Funding; Isofol: Research Funding; GlaxoSmithKline GSK: Research Funding; Mersana Therapeutics: Research Funding; Macrogenics: Research Funding; Celgene Corporation: Research Funding; Boehringer Ingelheim: Research Funding; Array: Membership on an entity's Board of Directors or advisory committees; Ciclomed LLC: Research Funding; AbbVie, Inc.: Research Funding; AstraZeneca: Research Funding; Bristol-Myers Squibb: Research Funding; Syros: Membership on an entity's Board of Directors or advisory committees; Exelxis: Membership on an entity's Board of Directors or advisory committees. Koucheki:MacroGenics, Inc.: Current Employment, Current equity holder in publicly-traded company. Sun:MacroGenics, Inc.: Current Employment, Current equity holder in publicly-traded company. Li:MacroGenics, Inc.: Current Employment, Current equity holder in publicly-traded company. Chen:MacroGenics, Inc.: Current Employment, Current equity holder in publicly-traded company. Zhang:MacroGenics, Inc.: Current Employment, Current equity holder in publicly-traded company. Muth:MacroGenics, Inc.: Current Employment, Current equity holder in publicly-traded company. Kaminker:MacroGenics, Inc.: Current Employment, Current equity holder in publicly-traded company. Moore:MacroGenics, Inc.: Current Employment, Current equity holder in publicly-traded company. Sumrow:MacroGenics, Inc.: Current Employment, Current equity holder in publicly-traded company.
APA, Harvard, Vancouver, ISO, and other styles
2

Baltas, M., J. D. Bastide, L. Cazaux, L. Gorrichon-Guigon, P. Maroni, and P. Tisnes. "Zinc(II) complexes of sulfinamides—II. t-Butyl N-(hydroxyphenyl) and t-butyl N-(o-aminophenyl) sulfinamoyl acetates." Spectrochimica Acta Part A: Molecular Spectroscopy 41, no. 6 (January 1985): 793–96. http://dx.doi.org/10.1016/0584-8539(85)80023-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ha, Kwang. "Crystal structure of (1,4,8,11-tetraazacyclotetradecane-κ4N,N′,N′′,N′′′)palladium(II) tetracyanonickelate(II), C14H24N8NiPd." Zeitschrift für Kristallographie - New Crystal Structures 235, no. 1 (December 18, 2019): 77–78. http://dx.doi.org/10.1515/ncrs-2019-0497.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Doğan, F., M. Ulusoy, Ö. F. Öztürk, İ. Kaya, and B. Salih. "Thermal studies of Co(II), Ni(II) and Cu(II) complexes of N,N′-bis(3,5-Di-t-butylsalicylidene)ethylenediamine." Journal of Thermal Analysis and Calorimetry 96, no. 1 (March 12, 2009): 267–76. http://dx.doi.org/10.1007/s10973-008-8980-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ha, Kwang. "Crystal structure of cyclo[tetra(μ2-cyanido)-tetracyanido-bis(1,4,7,10-tetraazacyclododecane-κ4N,N′,N′′,N′′′)dinickel(II)dipalladium(II)] hexahydrate, C24H52N16Ni2O6Pd2." Zeitschrift für Kristallographie - New Crystal Structures 235, no. 1 (December 18, 2019): 201–2. http://dx.doi.org/10.1515/ncrs-2019-0574.

Full text
Abstract:
AbstractC24H52N16Ni2O6Pd2, monoclinic, P21/c (no. 14), a = 8.6416(3) Å, b = 14.2237(5) Å, c = 15.5573(5) Å, β = 93.8054(12)°, V = 1908.02(11) Å3, Z = 2, Rgt(F) = 0.0312, wRref(F2) = 0.0915, T = 223(2) K.
APA, Harvard, Vancouver, ISO, and other styles
6

Maher, P. J. "Commutator and self-commutator approximants II." Filomat 24, no. 4 (2010): 1–7. http://dx.doi.org/10.2298/fil1004001m.

Full text
Abstract:
We minimize the quantities (i) ||T -(AX-X A) ||, (ii) ||T -(X*X-XX*)|| and (iii) ||T -(AX - X B)|| where T is isometric and where in (i) A is paranormal and commutes with T , in (ii) X*(or X ) is paranormal and commutes with T , and in (iii) A and B are paranormal and AT = T B and T A = BT. The upshot is that these quantities are minimized when 0 = AX - XA = X*X - XX*= AX - XB. To prove these results we obtain the power norm equality for paranormal operators: if A is paranormal then ||An|| = ||A||n if n?N.
APA, Harvard, Vancouver, ISO, and other styles
7

Killinger, William A., Thomas W. Rice, David J. Adelstein, Sharon V. Medendorp, Gregory Zuccaro, Thomas J. Kirby, and John R. Goldblum. "Stage II esophageal carcinoma: The significance of T and N." Journal of Thoracic and Cardiovascular Surgery 111, no. 5 (May 1996): 935–40. http://dx.doi.org/10.1016/s0022-5223(96)70367-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kim, Kang-Woo, and Jinhee Kim. "Crystal structure of bis(N,N,N-triethylammonium) bis(tetraselenido-κ2Se1,Se4)palladate(II), C12H32N2PdSe8." Zeitschrift für Kristallographie - New Crystal Structures 230, no. 3 (September 1, 2015): 269–70. http://dx.doi.org/10.1515/ncrs-2014-9015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Baltas, M., J. D. Bastide, A. de Blic, L. Cazaux, L. Gorrichon-Guigon, P. Maroni, M. Perry, and P. Tisnes. "Zinc(II) complexes of sulfinamides—I. N-Phenyl 2-propane sulfinamide, t-butyl N-phenyl and t-butyl N-cyclohexyl sulfinamoyl acetates." Spectrochimica Acta Part A: Molecular Spectroscopy 41, no. 6 (January 1985): 789–92. http://dx.doi.org/10.1016/0584-8539(85)80022-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mao, Pan-Dong, Xiao-Lei Zhao, Qing-Wen Yang, Miao Yang, and Yuan Wang. "Crystal structure of [N,N-bis((pyrrol-2-yl)ethylidene)butane-1,4-diamine-κ4N,N′,N′′,N′′′]-nickel(II), C16H20N4Ni." Zeitschrift für Kristallographie - New Crystal Structures 233, no. 1 (January 26, 2018): 101–2. http://dx.doi.org/10.1515/ncrs-2017-0190.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Ma, J. Y., T. X. Wu, X. G. She, and X. F. Pan. "Crystal structure of dichloro((N-(N′,N′-dimethylammonio)ethyl)- 2,4-dichlorosalicylaldiminato-N,O)copper(II), Cu(C11H14Cl2N2O)Cl2." Zeitschrift für Kristallographie - New Crystal Structures 221, no. 1 (March 2006): 53–54. http://dx.doi.org/10.1524/ncrs.2006.221.1.53.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Kim, Kang-Woo, and Di Wang. "Crystal structure of bis(N,N,N-ethyldimethylethanaminium) bis(heptaselenido-κ2Se1,Se7)palladate(II), C12H32N2PdSe14." Zeitschrift für Kristallographie - New Crystal Structures 232, no. 6 (November 27, 2017): 965–67. http://dx.doi.org/10.1515/ncrs-2017-0101.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Blom, Burgert, Günter Klatt, Daniel Gallego, Gengwen Tan, and Matthias Driess. "Unprecedented silicon(ii)→calcium complexes with N-heterocyclic silylenes." Dalton Transactions 44, no. 2 (2015): 639–44. http://dx.doi.org/10.1039/c4dt03148b.

Full text
Abstract:
The first N-heterocyclic silylene (NHSi) complexes of any s-block element to date are reported for calcium: [(η5-C5Me5)2Ca←:Si(O-C6H4-2-tBu){(NtBu)2CPh}] and [(η5-C5Me5)2Ca←:Si(NtBuCH)2]. The synthesis, structure, bonding analysis by DFT methods and the reactivity towards oxygen containing substrates is discussed.
APA, Harvard, Vancouver, ISO, and other styles
14

Ha, Kwang. "Crystal structure of catena-poly[(1,4,8,11-tetraazacyclotetradecane-κ 4 N,N′,N″,N′′′)-bis(μ 2-thiocyanato-κ2 N:S)-bis(thiocyanato-κS)-nickel(II)palladium(II)], C14H24N8NiPdS4." Zeitschrift für Kristallographie - New Crystal Structures 236, no. 3 (February 15, 2021): 631–33. http://dx.doi.org/10.1515/ncrs-2021-0025.

Full text
Abstract:
Abstract C14H24N8NiPdS4, triclinic, P 1 ‾ $P‾{1}$ (no. 2), a = 12.0330(8) Å, b = 12.0959(8) Å, c = 15.9551(12) Å, α = 85.768(3)°, β = 71.917(3)°, γ = 87.899(3)°, V = 2201.3(3) Å3, Z = 4, R gt (F) = 0.0379, wR ref (F 2) = 0.0973, T = 223 K.
APA, Harvard, Vancouver, ISO, and other styles
15

Cheng, M. Q., L. F. Ma, and L. Y. Wang. "Crystal structure of (phenanthroline-N,N′)-N-carbamoylmethyl-iminodiacetato- copper(II) dihydrate, [Cu(C6H8N2)(C12H8N2)] · 2H2O." Zeitschrift für Kristallographie - New Crystal Structures 221, no. 3 (September 2006): 369–71. http://dx.doi.org/10.1524/ncrs.2006.0114.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Arslan, H., D. Vanderveer, F. Emen, and N. Külcü. "Crystal structure of cis-bis(N,N-dimethyl-N′-4-chlorobenzoylthioureato) palladium(II), Pd(C10H10ClN2OS)2." Zeitschrift für Kristallographie - New Crystal Structures 218, no. 4 (December 2003): 479–80. http://dx.doi.org/10.1524/ncrs.2003.218.4.479.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Tan, Yee Seng, and Edward R. T. Tiekink. "Crystal structure of bis(μ-N-i-propyl-N-n-propyldithiocarbamato-κ2S:S′) bis(N-i-propyl-N-n-propyldithiocarbamato-κ2S,S′)dizinc(II), C28H56N4S8Zn2." Zeitschrift für Kristallographie - New Crystal Structures 233, no. 3 (May 24, 2018): 477–79. http://dx.doi.org/10.1515/ncrs-2017-0366.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Wang, Xinfang. "Crystal structure of tris(1,10-phenanthroline-N,N')manganese(II)dichloro octahydrate, C36H40Cl2MnN6O8." Zeitschrift für Kristallographie - New Crystal Structures 228, no. 1 (March 1, 2013): 5–6. http://dx.doi.org/10.1524/ncrs.2013.0003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Xu, Zhi-Hong, Ye Shen, and Wei-Na Wu. "Crystal structure of dinitrato-(N′-((quinolin-8-yl)methylene)isonicotinohydrazide κ3-N,N′,O)copper(II), C16H12N6O7Cu." Zeitschrift für Kristallographie - New Crystal Structures 233, no. 2 (March 28, 2018): 309–10. http://dx.doi.org/10.1515/ncrs-2017-0307.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Wang, Di, Hoseop Yun, and Kang-Woo Kim. "Crystal structure of bis(N,N,N-trimethylethanaminium) poly[bis(μ2-heptaselenido-κ2Se1,Se7)palladate(II)], C10H28N2PdSe14." Zeitschrift für Kristallographie - New Crystal Structures 232, no. 6 (November 27, 2017): 995–97. http://dx.doi.org/10.1515/ncrs-2017-0126.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Kiwada, Tatsuto, Hiromu Katakasu, and Akira Odani. "Crystal structure of (N-benzylpropane-1,3-diamine-κ2N, N′)(2,2′-bipyridine-κ2N,N′)platinum(II) chloride, C20H24Cl2N4Pt." Zeitschrift für Kristallographie - New Crystal Structures 234, no. 3 (March 26, 2019): 539–41. http://dx.doi.org/10.1515/ncrs-2018-0543.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Ha, Kwang. "Crystal structure of poly[tetra(μ 2-cyanido-κ2 N:O)-bis(N,N-dimethylformamide-κO)-manganese(II)-platinum(II)], C10H14MnN6O2Pt." Zeitschrift für Kristallographie - New Crystal Structures 236, no. 3 (February 11, 2021): 613–14. http://dx.doi.org/10.1515/ncrs-2021-0028.

Full text
Abstract:
Abstract C10H14MnN6O2Pt, monoclinic, C2/m (no. 12), a = 15.8030(7) Å, b = 7.6794(3) Å, c = 7.0970(3) Å, β = 110.8462(17)°, V = 804.89(6) Å3, Z = 2, R gt (F) = 0.0108, wR ref (F 2) = 0.0266, T = 223 K.
APA, Harvard, Vancouver, ISO, and other styles
23

Tan, Yee Seng, and Edward R. T. Tiekink. "Crystal structure of bis(μ-N-i-propyl-N-n-propyldithiocarbamato-κ3S,S′:S)bis(N-i-propyl-N-n-propyldithiocarbamato-κ2S,S′)dicadmium(II), C28H56Cd2N4S8." Zeitschrift für Kristallographie - New Crystal Structures 233, no. 3 (May 24, 2018): 481–83. http://dx.doi.org/10.1515/ncrs-2017-0367.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Patterson, Richard, and Ekrem Savaș. "On double sequences of continuous functions having continuous P-limits II." Filomat 27, no. 5 (2013): 931–35. http://dx.doi.org/10.2298/fil1305931p.

Full text
Abstract:
The goal of this paper is to relax the conditions of the following theorem: Let A be a compact closed set; let the double sequence of function s1,1 (x), s1,2 (x) s1,3 (x) . . . s2,1 (x), s2,2 (x) s2,3 (x) . . . s3,1 (x), s3,2 (x) s3,3 (x) . . . have the following properties: 1. for each (m, n) sm,n (x) is continuous in A; 2. for each x in A we have P - limm,n sm,n (x) = s(x); 3. s(x) is continuous in A; 4. there exists M such that for all (m, n) and all x in A |sm,n (x)| ? M. Then there exists a T -transformation such that P lim ?m,n (x) = s(x) uniformly in A m,n and to that end we obtain the following. In order that the transformation be such that P - lim s?s0 (S);t?t0 (T) ?(s; t; x) = 0 uniformly with respect x for every double sequence of continuous functions (sm,n (x)) define over A such that sm,n (x) is bounded over A and for all (m, n) and P - limm,n sm,n (x) = 0 over A it is necessary and sufficient that P - lim ?,? ? |ak,l (s, t)| = 0. s?s0 (S);t?t0 (T) k,l=1,1 .
APA, Harvard, Vancouver, ISO, and other styles
25

Lee, Sungchul. "The central limit theorem for Euclidean minimal spanning trees II." Advances in Applied Probability 31, no. 04 (December 1999): 969–84. http://dx.doi.org/10.1017/s0001867800009551.

Full text
Abstract:
Let X i : i ≥ 1 be i.i.d. points in ℝ d , d ≥ 2, and let T n be a minimal spanning tree on X 1,…,X n . Let L(X 1,…,X n ) be the length of T n and for each strictly positive integer α let N(X 1,…,X n ;α) be the number of vertices of degree α in T n . If the common distribution satisfies certain regularity conditions, then we prove central limit theorems for L(X 1,…,X n ) and N(X 1,…,X n ;α). We also study the rate of convergence for EL(X 1,…,X n ).
APA, Harvard, Vancouver, ISO, and other styles
26

Yamaguchi, Jun-ichi, Yuji Shusa, and Takayuki Suyama. "A convenient transformation of N-substituted ureas into N-(t-butoxycarbonyl)amines using a copper(II) salt-lithium t-butoxide system." Tetrahedron Letters 40, no. 47 (November 1999): 8251–54. http://dx.doi.org/10.1016/s0040-4039(99)01751-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

BOYLAN, MATTHEW, and KEN ONO. "PARITY OF THE PARTITION FUNCTION IN ARITHMETIC PROGRESSIONS, II." Bulletin of the London Mathematical Society 33, no. 5 (September 2001): 558–64. http://dx.doi.org/10.1112/s0024609301008438.

Full text
Abstract:
Let p(n) denote the ordinary partition function. Subbarao conjectured that in every arithmetic progression r (mod t) there are infinitely many integers N ≡ r (mod t) for which p(N) is even, and infinitely many integers M ≡ r (mod t) for which p(M) is odd. We prove the conjecture for every arithmetic progression whose modulus is a power of 2.
APA, Harvard, Vancouver, ISO, and other styles
28

Mphure, Lebohang Theodora, Hendrik G. Visser, Andreas Roodt, and Alice Brink. "Crystal structure of dichloro-N,N-bis(pyridine-2-ylmethyl)cyclohexamino copper(II), C18H23Cl2CuN3." Zeitschrift für Kristallographie - New Crystal Structures 230, no. 2 (June 1, 2015): 156–58. http://dx.doi.org/10.1515/ncrs-2014-9042.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Zheng, Y. Q., and Z. P. Kong. "Crystal structure of monoaqua(1,10-phenanthroline-N,N′)- succinatocobalt(II), Co(H2O)(C12H8N2)(C4H4O4)." Zeitschrift für Kristallographie - New Crystal Structures 218, no. 2 (June 2003): 223–24. http://dx.doi.org/10.1524/ncrs.2003.218.2.223.

Full text
Abstract:
Abstract C16H14CoN2O5, triclinic, P1 (No. 2), a = 7.499(1) Å, b = 10.270(1) Å, c = 10.490(1) Å, α = 97.65(1)°, β = 106.80(1)°, γ = 100.57(1)°, V = 745.3 Å3, Z = 2, Rgt(F) = 0.058, wRref(F2) = 0.151, T = 293 K.
APA, Harvard, Vancouver, ISO, and other styles
30

Wang, Li. "Automorphism Groups of the Imprimitive Complex Reflection Groups II." Algebra Colloquium 18, no. 02 (June 2011): 315–26. http://dx.doi.org/10.1142/s1005386711000216.

Full text
Abstract:
We prove that the automorphism group Aut (m,p,n) of an imprimitive complex reflection group G(m,p,n) is the product of a normal subgroup T(m,p,n) by a subgroup R(m,p,n), where R(m,p,n) is the group of automorphisms that preserve reflections and T(m,p,n) consists of automorphisms that map every element of G(m,p,n) to a scalar multiple of itself.
APA, Harvard, Vancouver, ISO, and other styles
31

Jing, Chen, Zhang Lingcong, Chen Jingwen, and Zhang Haodong. "Crystal structure of [tris(2-benzimidazolylmethyl)amine-κ4N,N′,N′′,N′′′]-[(pyridine-2,6-dicarboxylato-κ2O,N)]cadmium(II)–methanol (1:3) C34H36CdN8O7." Zeitschrift für Kristallographie - New Crystal Structures 233, no. 6 (November 27, 2018): 1047–49. http://dx.doi.org/10.1515/ncrs-2018-0162.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Li, Li. "Crystal structure of bis[3-methoxy-N-(1-(pyrazin-2-yl)ethylidene)benzohydrazonato-κ3O,N,N′]nickel(II), C28H26N8O4Ni." Zeitschrift für Kristallographie - New Crystal Structures 235, no. 5 (August 26, 2020): 1063–64. http://dx.doi.org/10.1515/ncrs-2020-0170.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Deng, Xiao-Wei, and Wei-Na Wu. "Crystal structure of bis(3-methoxy-N-(1-(pyridin-2-yl)ethylidene)benzohydrazonato κ3O,N,N′)zinc(II), C30H28N6O4Zn." Zeitschrift für Kristallographie - New Crystal Structures 235, no. 2 (February 25, 2020): 421–22. http://dx.doi.org/10.1515/ncrs-2019-0726.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Yang, Xue-Mei, Tao Zhu, and Long Lin. "Crystal structure of bis(3-methyl-N-(1-(pyrazin-2-yl)ethylidene)benzohydrazonato-κ3O,N,N′)nickel(II), C28H26N8O2Ni." Zeitschrift für Kristallographie - New Crystal Structures 235, no. 3 (April 28, 2020): 585–86. http://dx.doi.org/10.1515/ncrs-2019-0833.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Ok, Seung Ryong, and Dieter W. Gruenwedel. "Differential Effect of Hg(II) on [d(A)n · d(T)n] and [d(A-T)n · d(A-T)n] Sequences: Circular Dichroism (CD) Measurements and Endonuclease Digestion Studies Using Poly[d(A) · d(T)] and Poly[d(A-T) · d(A-T)] as Substrates." Zeitschrift für Naturforschung C 48, no. 5-6 (June 1, 1993): 488–94. http://dx.doi.org/10.1515/znc-1993-5-614.

Full text
Abstract:
Abstract The long-wavelength positive CD bands of poly[d(A) · d(T)] and poly[d(A-T) · d(A-T)] become inverted upon the addition of Hg(ClO4)2. Poly[d(A) · d(T)] requires higher levels of mercury to undergo inversion than poly[d(A-T) · d(A-T)]. Mercurated poly[d(A) d(T)] is digested more rapidly than the control by DNase I or staphylococcal nuclease at low levels of Hg(ClO4)2. Let r = [Hg(ClO4)2]added/[DNA-P]. A 4- to 5-fold rate increase occurs with DNase I at r = 0.25; a 2-fold increase with staphylococcal nuclease at r = 0.2. By contrast, digestion of poly[d(A-T )· d(A-T)] decreases immediately with increasing r. The noted rate increases appear to be due to a modification of poly[d(A)-d(T)] helix structure prior to the chiroptical conversion. The modification is interpreted as a widening of the minor groove, permitting, thus, a better binding of DNase I to its substrate. The overall changes in CD as well as enzymatic digestion rates are taken to signal mercury-induced alterations in helix screwness from rightto- left. They are totally reversible subsequent to the removal of mercury.
APA, Harvard, Vancouver, ISO, and other styles
36

Rivada-Wheelaghan, Orestes, Bruno Donnadieu, Celia Maya, and Salvador Conejero. "T-Shaped Platinum(II) Complexes Stabilised by Bulky N-Heterocyclic Carbene Ligands." Chemistry - A European Journal 16, no. 34 (July 23, 2010): 10323–26. http://dx.doi.org/10.1002/chem.201000955.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Balibrea, F., and A. Linero. "Periodic structure of $ \sigma $-permutation maps II. The case $ \mathbb{T}^{n} $." aequationes mathematicae 64, no. 1-2 (August 2002): 34–52. http://dx.doi.org/10.1007/s00010-002-8029-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Ishikawa, Yuki, Keiko Miyamoto, and Ernst Horn. "Crystal structure of trans-diacetonitrile diaqua(N,N,N',N'-tetramethylethylenediamine) nickel(II) diiodide, [Ni(tmen)(CH3CN)2(H2O)2]2+·2I–, C10H26I2N4NiO2." Zeitschrift für Kristallographie - New Crystal Structures 228, no. 2 (June 1, 2013): 167–68. http://dx.doi.org/10.1524/ncrs.2013.0049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

He, H. Y., Y. L. Zhou, and L. G. Zhu. "Crystal structure of triaqua(1,10-phenanthroline-N,N′)sulfatonickel(II), Ni(H2O)3(C12H8N2)SO4." Zeitschrift für Kristallographie - New Crystal Structures 218, no. 4 (December 2003): 563–64. http://dx.doi.org/10.1524/ncrs.2003.218.4.563.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Gao, Xiao-Li, Rong-Li Geng, and Pai Chen. "Crystal structure of bis-[N-(1-pyrazin-2-yl-ethylidene)-cyanoacetic acid-hydrazonato-κ3O,N,N′)]-zinc(II), C18H16N10O2Zn." Zeitschrift für Kristallographie - New Crystal Structures 235, no. 2 (February 25, 2020): 503–4. http://dx.doi.org/10.1515/ncrs-2019-0813.

Full text
Abstract:
AbstractC18H16N10O2Zn, triclinic, P1̄ (no. 2), a = 10.218(7) Å, b = 10.490(7) Å, c = 11.101(8) Å, α = 79.590(11)°, β = 65.913(12)°, γ = 66.785(10)°, V = 998.0(12) Å3, Z = 2, Rgt(F) = 0.0516, wRref(F2) = 0.1323, T = 293(2) K.
APA, Harvard, Vancouver, ISO, and other styles
41

Dani, S. G. "On orbits of unipotent flows on homogeneous spaces, II." Ergodic Theory and Dynamical Systems 6, no. 2 (June 1986): 167–82. http://dx.doi.org/10.1017/s0143385700003382.

Full text
Abstract:
AbstractWe show that if (ut) is a one-parameter subgroup of SL (n, ℝ) consisting of unipotent matrices, then for any ε > 0 there exists a compact subset K of SL(n, ℝ)/SL(n, ℤ) such that the following holds: for any g ∈ SL(n, ℝ) either m({t ∈ [0, T] | utg SL (n, ℤ) ∈ K}) > (1 – ε)T for all large T (m being the Lebesgue measure) or there exists a non-trivial (g−1utg)-invariant subspace defined by rational equations.Similar results are deduced for orbits of unipotent flows on other homogeneous spaces. We also conclude that if G is a connected semisimple Lie group and Γ is a lattice in G then there exists a compact subset D of G such that for any closed connected unipotent subgroup U, which is not contained in any proper closed subgroup of G, we have G = DΓ U. The decomposition is applied to get results on Diophantine approximation.
APA, Harvard, Vancouver, ISO, and other styles
42

Ha, Kwang. "Crystal structure of (1,4,8,11-tetraazacyclotetradecane)palladium(II) tetracyanopalladate(II), C14H24N8Pd2." Zeitschrift für Kristallographie - New Crystal Structures 232, no. 1 (January 1, 2017): 139–40. http://dx.doi.org/10.1515/ncrs-2016-0193.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Ou, Guang-Chuan, Qiang Zhou, and Qiong Wang. "Crystal structure of (4-aminobenzoato-κ2O,O′)-[5,5,7,12,12,14-hexamethyl-1,4,8,11-tetraazacyclotetradecane-κ4N,N′,N′′,N′′′]nickel(II) perchlorate monohydrate, C23H44ClN5NiO7." Zeitschrift für Kristallographie - New Crystal Structures 235, no. 5 (August 26, 2020): 1095–97. http://dx.doi.org/10.1515/ncrs-2020-0184.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Ma, Ning, and Ye Wang. "Crystal structure of tetraaqua dinitrato-κ2O,O'-4,4',6,6'-tetramethyl-2,2'- bipyrimidine-κ4N,N':N'',N''' dinickel(II) dinitrate, C6H11N4NiO8." Zeitschrift für Kristallographie - New Crystal Structures 229, no. 2 (June 1, 2014): 109–10. http://dx.doi.org/10.1515/ncrs-2014-0057.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Jin, Q. H., L. Yang, X. L. Xin, H. W. Gao, J. C. Dong, and P. Z. Li. "Crystal structure of aqua(phenanthroline-N,N′)(glycinato-N,O)copper(II) bromide hydrate, [Cu(NH2CH2COO)(C12H8N2)(H2O)]Br · H2O." Zeitschrift für Kristallographie - New Crystal Structures 221, no. 3 (September 2006): 383–84. http://dx.doi.org/10.1524/ncrs.2006.0120.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Antolini, Floria, Peter B. Hitchcock, Alexei V. Khvostov, and Michael F. Lappert. "Synthesis and characterization of N-silylated, C1-symmetric benzamidinates of lithium, sodium, and tin(II)." Canadian Journal of Chemistry 84, no. 2 (February 1, 2006): 269–76. http://dx.doi.org/10.1139/v05-250.

Full text
Abstract:
The synthesis and characterization of complexes obtained from the reactions between Li[N-t-Bu(SiMe3)] (A) or the sodium analogue Na[N-t-Bu(SiMe3)] (B) and the cyanoarene RCN (R = Ph or 4-MeOC6H4) are discussed. These are the THF adduct [Li{µ-cis-N(t-Bu)C(Ph)N(SiMe3)}(THF)]2 (1), the TMEDA adduct Li[N(t-Bu)C(Ph)N(SiMe3)](TMEDA) (2), the neutral ligand-free lithium benzamidinate Li[N(t-Bu)C(C6H4OMe-4)N(SiMe3)] (3), and the THF adduct Li[N(t-Bu)C(C6H4OMe-4)N(SiMe3)](THF) (3a). The preparation and structure of the crystalline compound [Na{µ-cis-N(t-Bu)C(Ph)N(SiMe3)}(OEt2)]2 (4) is described. From the lithium benzamidinate 1 and Sn(II) chloride the tin(II) complex [Sn{N(t-Bu)C(Ph)N(SiMe3)}2] (5) was obtained. The molecular structures of the crystalline compounds 1, 4, and 5 were established by X-ray diffraction. In 1 and 4 the benzamidinato ligand is both chelating and bridging, with the Me3Si-substituted nitrogen atom as the bridging site. The central planar (MN)2 four-membered ring is a rhombus in 1, with almost equal Li—N bond lengths, whereas in 4 the bonds to Na(1) are significantly longer than those to Na(2). In 5, the ligand is N,N′-chelating. Key words: alkali metals, tin(II), benzamidinates, NMR spectra, X-ray structures.
APA, Harvard, Vancouver, ISO, and other styles
47

Yun, Zhao, Xu Lu, and Zhang Li-Fang. "Crystal structure of (tris(2-pyridylmethyl)amine-κ4N,N′,N′′,N′′′′)-chloranilato-κO,O′-zinc(II) – methanol (1/1), C25H22Cl2N4O5Zn." Zeitschrift für Kristallographie - New Crystal Structures 232, no. 2 (March 1, 2017): 275–77. http://dx.doi.org/10.1515/ncrs-2016-0237.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Guse, A. H., E. Roth, and F. Emmrich. "Intracellular Ca2+ pools in Jurkat T-lymphocytes." Biochemical Journal 291, no. 2 (April 15, 1993): 447–51. http://dx.doi.org/10.1042/bj2910447.

Full text
Abstract:
Jurkat T-lymphocytes comprise at least four intracellular Ca2+ pools. Pool I was agonist-sensitive and contained 23 +/- 8% (n = 18) of the total Ca(2+)-storage capacity, as shown in intact cells in the presence of EGTA. The time courses of the agonist-induced formation of Ins(1,4,5)P3 and of the Ca2+ release from pool I were nearly superimposable, indicating that the agonist-sensitive pool I is emptied by Ins(1,4,5)P3. Likewise, in permeabilized cells, the size of the Ins(1,4,5)P3-sensitive Ca2+ pool I was 27 +/- 11% (n = 14). Pool II contained 26 +/- 5% (n = 9) of intracellularly stored Ca2+ and was liberated by thapsigargin, an inhibitor of the endoplasmic-reticulum (ER) Ca(2+)-ATPase. Addition of thapsigargin before addition of agonist abolished the agonist-induced Ca2+ release in both intact and permeabilized cells, indicating that pool I is a subcompartment of the ER Ca2+ pool. The content of this ER Ca2+ pool (pools I and II) amounted to 51 +/- 15% (n = 9) in intact cells and 49 +/- 16% (n = 16) in permeabilized cells. Caffeine released Ca2+ even when the ER pool (pools I and II) was emptied by previous addition of thapsigargin, indicating the presence of a third pool independent of pools I and II. Pool III contained 23 +/- 6% (n = 8) in intact cells, but 41 +/- 8% (n = 5) in permeabilized cells. The remaining intracellularly stored Ca2+ was released by addition of the Ca2+ ionophore ionomycin. This fourth pool contained 27 +/- 8% (n = 9) in intact cells, but less than 10% in permeabilized cells. The size of pool III was increased when pools I and II were emptied before addition of caffeine, whereas the size of pool IV was decreased under such conditions. In conclusion, this first comprehensive description of intracellular Ca2+ pools in Jurkat T-lymphocytes demonstrates the presence of four different Ca2+ pools, provides estimates of their sizes and describes relationships between each other. Release of Ca2+ from pool I [Ins(1,4,5)P3-sensitive] has previously been shown to play a major role in T-cell activation, whereas the physiological role of pools II-IV remains to be established.
APA, Harvard, Vancouver, ISO, and other styles
49

Li, Ji, and Ming-Zhi Miao. "The crystal structure of aqua{N,N,N′,N′-tetrakis[(1H-benzimidazol-κN3) methyl]cyclohexane-1,2-diamine}lead(II) diacetate–methanol (1/2), C44H54N10O7Pb." Zeitschrift für Kristallographie - New Crystal Structures 235, no. 6 (October 27, 2020): 1417–20. http://dx.doi.org/10.1515/ncrs-2020-0343.

Full text
Abstract:
AbstractPbC44H54N10O7, triclinic, P1̄ (no. 2), a = 12.096(2) Å, b = 12.916(2) Å, c = 16.5904(7) Å, α = 101.163(2)°, β = 110.634(2)°, γ = 100.698(2)°, V = 2287.0(4) Å3, Z = 2, Rgt(F) = 0.0604, wRref(F2) = 0.1409, T = 298(2) K.
APA, Harvard, Vancouver, ISO, and other styles
50

Shirvan, Sadif A., Moayad Hossaini Sadr, and Karim Zare. "Crystal structure of 2,2'-biqinoline-κ2N,N')dichloromercury(II), C18H12Cl2HgN2." Zeitschrift für Kristallographie - New Crystal Structures 230, no. 3 (September 1, 2015): 247–48. http://dx.doi.org/10.1515/ncrs-2015-0013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'N.T. Luke II' for other source types:
Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography